Register your interest and estimated travel costs
The annual meeting is coming closer and a program-at-a-glance can be found here. We invite all of you who are planning to join us at the Turkish Riviera on 28-30 September 2022 to fill in a short questionnaire about your travel plans. Note that we need this information to determine the level of reimbursement for travel for all attendees. You can find the link to this questionnaire here.
Submit your abstract!
During the meeting there will be room for all of you to present your current research or upcoming projects. Abstracts can be submitted via e-mail until Wednesday, August 17th, 2022 at 23.59h. GliMR abstract prices will be awarded during the meeting.
Two types of abstracts can be submitted: a ‘classic abstract’ and a ‘project abstract’. All abstracts should be categorized in one of those four topics:
-
Radiogenomics and imaging biomarker studies (RG)
-
Data management and knowledge transfer (DM)
-
Preclinical applications (PR)
-
Other (OT)
1 – Classic abstract
The ‘classic abstract’ presents results from a recently executed study or project. Abstracts containing data from a recently published study are allowed as well.
Follow the standard abstract structure: introduction, methods, results, discussion, references. Maximum one page.
Email subject: GliMR_classic_topic_NameResearcher
2 – Project abstract
The ‘project abstract’ allows researchers to present an ongoing or planned study or project. Reporting results is not mandatory. This type of abstract is open for all members, but mainly encourages early career researchers to present their work. It offers the opportunity to set-up collaborations, open up discussion, or present remaining project issues. Maximum one page.
Email subject: GliMR_project_topic_NameResearcher
Submit your pipeline or software
During this meeting, there will be room to present your analysis pipeline or software. Applications can be submitted via
e-mail until Wednesday, August 17th, 2022 at 23.59h. Make sure you send a brief description about your analysis pipeline or software including MR modality/modalities of interest and (pre)clinical useability.
We hope to see you in Kusadasi!